Hypothyroidism: Symptoms, Causes, Diagnosis, and Treatment Guide

Hypothyroidism: Symptoms, Causes, Diagnosis, and Treatment Guide

Quick Answer: Hypothyroidism is an endocrine condition where an underactive thyroid fails to produce sufficient thyroid hormones, slowing metabolic rate throughout the body. Standard management involves daily oral levothyroxine therapy, regular blood monitoring of thyroid-stimulating hormone (TSH), and targeted lifestyle measures to maintain clinical stability.

Key Takeaways:

• The primary form of thyroid disorder hypothyroidism stems from autoimmune destruction, known as Hashimoto thyroiditis, which gradually diminishes hormone synthesis.
• Common clinical presentations involve fatigue, cold intolerance, modest weight gain, dry skin, and constipation resulting from diminished cellular energy expenditure.
• Blood tests measuring elevated serum TSH and low free thyroxine (free T4) provide standard laboratory confirmation of overt primary disease.
• Subclinical presentations require careful clinician evaluation, with daily levothyroxine therapy typically indicated when TSH concentrations exceed 10 mIU/L or during pregnancy.
• Patients affected by the July 2026 US FDA Class II recall of select Major Pharmaceuticals levothyroxine lots should verify their bottle with a pharmacist rather than discontinuing medication.

Hypothyroidism is a chronic endocrine condition marked by inadequate circulating levels of thyroid hormones. Situated in the anterior neck, the thyroid gland regulates the speed of biochemical processes across virtually every organ system. When hormone output drops, physiological processes decelerate, leading to systemic manifestations that range from mild lethargy to cardiovascular and metabolic complications.

Understanding Hypothyroidism and How It Affects Metabolism

Hypothyroidism occurs when the thyroid gland produces insufficient thyroid hormones (thyroxine, or T4, and triiodothyronine, or T3) to meet metabolic demands, resulting in a systemic slowdown of organ function, energy production, and cellular turnover.

The hypothalamic-pituitary-thyroid (HPT) axis governs this metabolic engine. Under normal physiological conditions, the hypothalamus secretes thyrotropin-releasing hormone (TRH), which prompts the anterior pituitary to release thyroid-stimulating hormone (TSH). TSH subsequently stimulates the thyroid gland to synthesize and release thyroxine (T4) and triiodothyronine (T3). While T4 represents roughly 80% to 90% of glandular output, peripheral tissues must enzymatically convert T4 into T3, the biologically active hormone, via deiodinase enzymes.

Thyroid hormones act on nuclear receptors present in nearly all nucleated human cells, regulating gene transcription for mitochondrial respiration, protein synthesis, and basal metabolic rate (BMR). When circulating hormone levels fall, the metabolic rate drops accordingly.

This deceleration impairs cellular processes throughout the body:

• Cardiovascular Dynamics: Reduced cardiac inotropy (contractile strength) and chronotropy (heart rate) decrease overall cardiac output, accompanied by increased systemic vascular resistance and diastolic blood pressure.
• Lipid Metabolism: Downregulation of low-density lipoprotein (LDL) receptors on hepatocytes impairs clearance, leading to elevated serum cholesterol and triglycerides.
• Thermogenesis: Diminished mitochondrial oxidative phosphorylation reduces core heat production, manifesting as systemic cold intolerance.
• Gastrointestinal Transit: Slower intestinal smooth muscle peristalsis delays bowel transit times, resulting in chronic constipation.
• Neuropsychiatric Function: Decreased cerebral blood flow and altered neurotransmitter signaling slow cognitive processing and disrupt mood regulation.

Recognizing Primary Hypothyroidism Symptoms

Hypothyroidism symptoms typically emerge gradually and include persistent fatigue, cold sensitivity, unexplained modest weight gain, constipation, dry skin, brittle hair, muscle aches, and depressed mood as cellular metabolism decelerates.

Because these manifestations develop insidiously over months or years, individuals frequently attribute their initial complaints to normal aging, work-related stress, or poor sleep. The clinical picture varies depending on patient age, sex, the rate of onset, and the depth of hormone deficiency. When patients first seek care for general thyroid problems, hypothyroidism symptoms often span both physical and psychological domains.

Common clinical presentations include:

• Energy and Mood: Profound, unrelenting fatigue that does not resolve with adequate sleep; apathy, psychomotor slowing, and cognitive impairment (often described by patients as "brain fog").
• Metabolic Changes: Modest, unexplained weight gain (typically 5 to 10 pounds, primarily driven by fluid retention and sodium accumulation rather than adipose tissue); intolerance to cold temperatures.
• Dermatological Signs: Dry, coarse, pale skin; reduced sweating; diffuse hair thinning; loss of the outer third of the eyebrows (madarosis); brittle, slow-growing nails.
• Musculoskeletal Complaints: Proximal muscle weakness, myalgias, arthralgias, and joint stiffness; fluid retention in the wrists can compress the median nerve, triggering secondary carpal tunnel syndrome.
• Gastrointestinal and Reproductive Effects: Chronic constipation due to reduced intestinal motility; menorrhagia (heavy menstrual bleeding) or irregular cycles in premenopausal women; reduced libido and fertility challenges across sexes.

In chronic or advanced deficiency, patients may develop non-pitting edema known as myxedema. This occurs when glycosaminoglycans, primarily hyaluronic acid, accumulate in the dermis and subcutaneous tissues. Physical signs include periorbital puffiness, an enlarged tongue (macroglossia), and a deep, hoarse voice caused by fluid accumulation within the vocal cords. Recognizing the early symptoms of hypothyroidism is critical, as prompt evaluation prevents progression into these advanced structural and neurological changes.

Primary and Secondary Causes of Hypothyroidism

The most frequent cause of hypothyroidism in iodine-sufficient countries is Hashimoto thyroiditis, an autoimmune disorder where the immune system destroys thyroid parenchyma; other causes include thyroidectomy, radioactive iodine therapy, radiation, specific medications, and rarely pituitary disorders.

Clinicians classify the causes of hypothyroidism into primary, secondary (central), and tertiary etiologies depending on where the physiological defect originates along the HPT axis.

Classification	Anatomical Site of Origin	Common Etiologies
Primary Hypothyroidism	Thyroid gland failure	• Hashimoto thyroiditis (chronic lymphocytic thyroiditis) • Surgical removal (total or partial thyroidectomy) • Radioactive iodine ablation (I-131) • External beam neck irradiation • Pharmacotherapy (lithium, amiodarone, checkpoint inhibitors) • Severe iodine deficiency or sustained iodine excess • Congenital thyroid dysgenesis
Central Hypothyroidism	Pituitary gland or hypothalamus	• Pituitary macroadenomas or craniopharyngiomas • Pituitary surgery, radiosurgery, or apoplexy • Sheehan syndrome (postpartum pituitary necrosis) • Traumatic brain injury (TBI) • Hypothalamic tumors or infiltrative disease disrupting TRH

Hashimoto Thyroiditis

Accounting for the vast majority of spontaneous cases in areas with iodized salt, Hashimoto thyroiditis (chronic lymphocytic thyroiditis) involves a breakdown of immune tolerance. Autoreactive CD4+ T-helper cells infiltrate the thyroid parenchyma, stimulating cytotoxic CD8+ T-cells and activating B-cells. These produce circulating antibodies against thyroid peroxidase (anti-TPO) and thyroglobulin (anti-Tg). Over time, follicular architecture collapses, follicles undergo oncocytic transformation (forming Hürthle cells), and fibrous tissue replaces active hormone-producing cells.

Iatrogenic and Treatment-Related Causes

Deficiency often results from medical interventions directed at other thyroid disorders, with hypothyroidism arising as an anticipated outcome:

• Surgical Resection: Total thyroidectomy for thyroid cancer or severe multinodular goiter results in immediate, lifelong dependence on exogenous hormone replacement. Lobectomy (hemithyroidectomy) leads to overt hypothyroidism in approximately 15% to 30% of patients, requiring ongoing surveillance.
• Radioactive Iodine (RAI): Administered for hyperthyroidism (such as Graves' disease) or toxic nodules, iodine-131 destroys follicular cells over 3 to 6 months, commonly transitioning the patient into lifelong hypothyroidism.
• External Beam Radiation: Radiation directed at the neck for lymphomas, laryngeal cancer, or nasopharyngeal malignancies often damages the adjacent thyroid tissue, with clinical failure manifesting several months to years post-treatment.

Medication-Induced Dysfunction

Several systemic medications can alter thyroid hormone synthesis, release, or metabolism:

• Lithium: Inhibits thyroid hormone release from follicular stores, occasionally causing goiter and hypothyroidism.
• Amiodarone: Contains high iodine concentrations that can provoke the Wolff-Chaikoff effect (inhibition of hormone synthesis) or trigger drug-induced destructive thyroiditis.
• Immune Checkpoint Inhibitors: Modern oncology therapies (such as pembrolizumab, nivolumab, and ipilimumab) can induce primary hypophysitis or destructive autoimmune thyroiditis, producing rapid thyroid failure.

Diagnostic Evaluation: Blood Test for Hypothyroidism

A definitive diagnosis of hypothyroidism requires blood testing for thyroid-stimulating hormone (TSH) and free thyroxine (free T4); an elevated TSH accompanied by low free T4 confirms overt primary hypothyroidism.

Relying solely on clinical symptoms is insufficient because signs like fatigue and weight changes are non-specific. Objective laboratory evaluation using an automated chemiluminescent blood test hypothyroidism panel provides the foundation for diagnosis and staging.

Core Laboratory Biomarkers

• Serum TSH: The primary screening test. Because the pituitary gland responds log-linearly to tiny fluctuations in circulating thyroid hormones, small drops in serum T4 trigger substantial spikes in TSH. Standard laboratory reference ranges typically run from 0.4 to 4.0 or 4.5 mIU/L, though age-specific adjustments apply to older populations.
• Free Thyroxine (Free T4): Measures the unbound, biologically active fraction of T4 in the blood (typically 0.8 to 1.8 ng/dL). Assessing free T4 is essential because total T4 measurements can be distorted by fluctuations in thyroid-binding globulin (TBG) caused by oral contraceptives, pregnancy, or liver disease.
• Free Triiodothyronine (Free T3): Generally not recommended for diagnosing hypothyroidism. The body upregulates the conversion of T4 to T3 via deiodinases in early thyroid failure, often keeping serum T3 levels within normal limits until hypothyroidism is severe and advanced.

Diagnostic Pattern	TSH Level	Free T4 Level	Clinical Interpretation	Recommended Next Step
Normal (Euthyroid)	0.4-4.0 mIU/L	0.8-1.8 ng/dL	Normal thyroid axis function	No intervention indicated
Overt Primary Hypothyroidism	Elevated (>4.5 mIU/L)	Decreased (<0.8 ng/dL)	Established thyroid gland failure	Initiate levothyroxine therapy
Subclinical Hypothyroidism	Elevated (>4.5 mIU/L)	Normal (0.8-1.8 ng/dL)	Mild or early thyroid dysfunction	Retest in 6-12 weeks; evaluate TPO antibodies
Central (Secondary) Hypothyroidism	Low or inappropriately normal	Decreased (<0.8 ng/dL)	Pituitary or hypothalamic failure	Brain/pituitary MRI; evaluate adrenal axis (ACTH/cortisol)

Autoantibody Testing

Testing for thyroid peroxidase antibodies (anti-TPO) helps identify the underlying etiology. Elevated anti-TPO titers confirm an autoimmune origin (Hashimoto thyroiditis) and signal an increased risk of progression from subclinical hypothyroidism to overt failure. Routine ultrasound imaging is unnecessary for standard hypothyroid presentations unless the clinician detects distinct nodules or marked gland asymmetry on physical exam.

Subclinical Hypothyroidism: Diagnosis and When to Treat

Subclinical hypothyroidism is diagnosed when serum TSH is elevated while circulating free T4 remains within reference limits; treatment with levothyroxine is generally recommended when TSH exceeds 10 mIU/L, during pregnancy, or in symptomatic individuals with positive thyroid peroxidase (TPO) antibodies.

Because transient factors, such as recovery from acute viral illness (subacute thyroiditis), severe systemic stress, or assay variability, can temporarily elevate TSH, clinicians do not base a long-term treatment plan on a single abnormal test. Current clinical guidelines recommend repeating serum TSH and free T4 measurements after a 6- to 12-week interval to confirm that the elevation persists.

Risk of Progression

Among individuals with confirmed subclinical thyroid dysfunction, the rate of progression to overt disease ranges between 2% and 5% per year. The presence of high anti-TPO antibody titers and baseline TSH levels above 8 to 10 mIU/L significantly increases this risk.

Baseline TSH Level	Free T4 Status	Patient Population	Management Recommendation
Confirmed TSH ≥ 10.0 mIU/L	Normal	All adult age groups	Initiate weight-adjusted levothyroxine to lower cardiovascular risk and relieve symptoms
Confirmed TSH 4.5-9.9 mIU/L	Normal	Adults < 65-70 years	Consider a 3- to 6-month trial of levothyroxine if symptomatic or anti-TPO positive
Confirmed TSH 4.5-9.9 mIU/L	Normal	Pregnant patients or women pursuing fertility	Initiate levothyroxine promptly, aiming for trimester-specific reference targets
Confirmed TSH 4.5-9.9 mIU/L	Normal	Adults ≥ 70-80 years	Watchful waiting preferred; avoid overtreatment risks such as atrial fibrillation and bone loss

In older adults, particularly those over 75, mild TSH elevations often represent a physiological adaptation rather than true pathology. Multiple clinical trials have shown that treating mild subclinical elevations in this demographic does not improve cognitive performance, fatigue, or cardiovascular outcomes, while increasing the risk of iatrogenic thyrotoxicosis.

Hypothyroidism and Treatment: Levothyroxine Management and Best Practices

The standard medicine for hypothyroidism is levothyroxine sodium, a synthetic T4 tablet taken once daily on an empty stomach with plain water at least 30 to 60 minutes before breakfast; dose adjustments are guided by repeat TSH testing 6 to 8 weeks after starting or altering the dose.

Levothyroxine acts as a steady prohormone. Once absorbed, peripheral deiodinase enzymes convert it into active T3, matching the body's natural physiology. Its long half-life of approximately 7 days ensures stable blood concentrations throughout the day with once-daily dosing.

Determining the Starting Dose

Clinicians individualize starting doses based on the patient's weight, age, and cardiac status:

• Full Replacement: For overt hypothyroidism in young, healthy adults, the standard initial dose is roughly 1.6 mcg per kilogram of ideal body weight daily.
• Partial Replacement: In subclinical disease, lower daily doses ranging between 25 and 50 mcg are generally sufficient to normalize serum TSH.
• Elderly or Cardiac Patients: In patients with coronary artery disease, heart failure, or advanced age, clinicians begin with conservative doses of 12.5 to 25 mcg daily. Increasing the dose gradually avoids precipitating myocardial ischemia or cardiac arrhythmias as metabolic demand rises.

Maximizing Absorption

Levothyroxine absorption occurs primarily within the jejunum and ileum, requiring an acidic gastric environment for dissolution. Approximately 60% to 80% of an oral dose enters circulation under optimal conditions.

To maintain reliable absorption, patients must follow specific daily routines:

• Timing: Take the tablet immediately upon waking with a full glass of plain water, waiting at least 30 to 60 minutes before eating breakfast or drinking coffee. Alternatively, patients may take it at bedtime, provided at least 3 to 4 hours have elapsed since their last meal.
• Interfering Compounds: Calcium carbonate, ferrous sulfate (iron), aluminum hydroxide antacids, sucralfate, and cholestyramine bind levothyroxine directly within the gut lumen. Patients must separate these supplements from their thyroid medication by at least 4 hours.
• Medications Affecting Gastric Acidity: Proton pump inhibitors (such as omeprazole and pantoprazole) and H2-receptor antagonists reduce stomach acid, impairing tablet dissolution and often requiring a slight increase in the levothyroxine dose.

Follow-up Protocol and Monitoring

Because levothyroxine requires 5 to 6 weeks to achieve pharmacodynamic steady state, clinicians order repeat TSH blood testing 6 to 8 weeks after initiating therapy or adjusting the dose.

Once serum TSH settles within the reference target (typically 0.5 to 2.5 mIU/L for most non-pregnant adults), monitoring intervals can extend to every 6 to 12 months, or sooner if the patient experiences significant weight changes, starts interfering medications, or develops recurring symptoms. Successful hypothyroidism and treatment balance requires maintaining consistent laboratory values alongside clinical symptom relief.

Medication Safety: Checking Your Prescription After the July 2026 Levothyroxine Recall

Following the July 2026 US FDA Class II recall of select Major Pharmaceuticals levothyroxine lots due to subpotency concerns, patients should consult their dispensing pharmacy to verify their lot number, but must continue taking their current medication until a verified replacement is issued to prevent worsening hypothyroid symptoms.

A Class II recall by the US Food and Drug Administration (FDA) in the United States denotes a scenario where exposure to a violative product may cause temporary or medically reversible adverse health consequences. In this instance, laboratory stability evaluations revealed that specific distributed lots of Major Pharmaceuticals levothyroxine sodium tablets fell below required potency specifications prior to their labeled expiration dates.

Subpotent tablets deliver a lower dose of active hormone than prescribed. Over several weeks, taking subpotent medication can lead to rising serum TSH levels and the return of hypothyroid symptoms, including progressive fatigue, mood changes, cold intolerance, constipation, and fluid retention.

Patients taking levothyroxine should follow these clear steps:

1. Check the Prescription Bottle: Examine the label for the manufacturer or repackager name. Look specifically for "Major Pharmaceuticals."
2. Locate the Lot Number: Check the printed lot number on the side of the medication bottle or pharmacy packaging.
3. Contact the Dispensing Pharmacy: Speak directly with the pharmacist to cross-reference your bottle's lot number against the US FDA recall inventory. Pharmacies maintain comprehensive records and can confirm whether your specific fill was part of the impacted batches.
4. Never Stop Therapy Abruptly: Discontinuing thyroid hormone replacement causes circulating T4 levels to fall rapidly, which can trigger severe metabolic and physical symptoms. Continue taking your current tablets until your pharmacist provides an unaffected replacement bottle.
5. Monitor for Symptom Changes: If you have been taking an affected lot and notice fatigue, cold sensitivity, or unexpected weight gain, alert your healthcare provider. Your physician can order a confirmatory TSH test to verify your thyroid axis remains stable.

Potential Complications and Monitoring Risks

Untreated hypothyroidism carries significant risks of systemic decline, while excessive levothyroxine supplementation can provoke cardiovascular instability and skeletal demineralization.

Thyroid hormone management requires balanced, measured clinical dosing. Leaving overt deficiency untreated allows metabolic waste products to accumulate, impairs cardiovascular function, and increases long-term morbidity. Conversely, over-replacing thyroid hormone exposes tissues to excess thyroid activity.

Risks of Untreated or Under-Treated Hypothyroidism

• Cardiovascular Compromise: Elevated systemic vascular resistance combined with secondary dyslipidemia accelerates atherosclerosis and increases the risk of coronary events. Chronic fluid accumulation can cause pericardial effusions.
• Neurological Decline: Sustained deficiency can cause peripheral sensorimotor neuropathy characterized by paresthesias, numbness, and progressive muscle weakness.
• Infertility and Pregnancy Complications: Unmanaged disease disrupts ovulatory cycles and increases the risk of preeclampsia, low birth weight, and neurodevelopmental delays in offspring.
• Myxedema Coma: The most severe complication of unmanaged hypothyroidism. Typically triggered by an acute event (such as infection, trauma, surgery, or cold exposure) in someone with longstanding, severe disease, it presents with hypothermia, severe bradycardia, hypoventilation, hyponatremia, and progressive obtundation. Myxedema coma is a life-threatening medical emergency requiring immediate local intensive care and intravenous hormone administration; patients with these warning signs should not delay treatment or attempt travel.

Risks of Iatrogenic Overtreatment

• Cardiac Arrhythmias: Suppressing TSH below normal reference limits through excess levothyroxine dosing increases the risk of supraventricular arrhythmias, particularly atrial fibrillation in adults over 60.
• Bone Demineralization: Excess thyroid hormone accelerates osteoclastic bone resorption beyond osteoblastic capacity, reducing bone mineral density and accelerating osteopenia or osteoporosis, which increases fracture risk in postmenopausal women.

Frequently Asked Questions

Does hypothyroidism cause weight gain?

Hypothyroidism leads to modest weight gain, typically between 5 and 10 pounds, which is primarily driven by water and salt retention rather than significant accumulation of body fat. Because thyroid hormones govern basal metabolic rate, an underactive gland reduces overall caloric expenditure, making weight loss harder to achieve. Once a patient begins proper levothyroxine treatment and TSH normalizes, the excess fluid weight typically resolves; however, thyroid hormone therapy should never be prescribed or used as an isolated weight-loss strategy.

Subclinical hypothyroidism: when to treat?

Treatment for subclinical hypothyroidism is generally indicated when serum TSH levels persistently reach or exceed 10.0 mIU/L, during pregnancy, or in women planning pregnancy to support fetal neurodevelopment. For individuals with TSH levels between 4.5 and 9.9 mIU/L, clinicians weigh treatment if the patient has bothersome hypothyroid symptoms, positive anti-TPO antibodies, or underlying cardiovascular disease. Routine treatment is typically discouraged in individuals over 70 with mild TSH elevations, as the risks of cardiac arrhythmias and bone loss outweigh the potential benefits.

How long does it take for levothyroxine to relieve symptoms?

Most patients begin experiencing symptomatic improvement within 2 to 3 weeks of initiating daily levothyroxine, but more substantial symptom relief often requires 6 to 8 weeks or longer as tissue levels normalize. Synthetic thyroxine has a 7-day half-life, meaning the body needs over a month of daily dosing to achieve stable tissue concentrations. Clinicians order follow-up blood tests at the 6- to 8-week mark to confirm the dose has normalized TSH, adjusting tablet strength if symptoms persist or laboratory targets are not met.

Can dietary supplements or kelp cure an underactive thyroid?

No dietary supplement can cure structural or autoimmune thyroid failure, and products containing kelp or bladderwrack can actually worsen the condition. Kelp contains variable, concentrated amounts of iodine that can trigger the Wolff-Chaikoff effect, causing an already compromised gland to further suppress hormone production. While ensuring adequate nutritional intake of selenium and zinc supports normal peripheral hormone conversion, synthetic levothyroxine remains the only established, medically validated therapy for restoring deficient thyroid hormone levels.